WallStSmart

Hinge Health, Inc. (HNGE)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 11078% more annual revenue ($72.25B vs $646.34M). LLY leads profitability with a 35.0% profit margin vs -78.9%. LLY earns a higher WallStSmart Score of 76/100 (B+).

HNGE

Avoid

34

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: -2.69

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 4.3Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HNGE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
47.2%10/10

Revenue surging 47.2% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$1.02T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

Areas to Watch

HNGE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
51.1x2/10

Trading at 51.1x book value

Return on EquityProfitability
-197.2%2/10

ROE of -197.2% — below average capital efficiency

EPS GrowthGrowth
-68.4%2/10

Earnings declined 68.4%

LLY4 concerns · Avg: 2.8/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

Debt/EquityHealth
1.393/10

Elevated debt levels

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Price/BookValuation
34.7x2/10

Trading at 34.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : HNGE

The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 47.2% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : HNGE

The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.

Bear Case : LLY

The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

HNGE profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (76/100 vs 34/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hinge Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?